Lv1
50 积分 2025-09-18 加入
Efficacy and safety of telitacicept in patients with class III–V lupus nephritis: A real-world retrospective cohort study
3个月前
已完结
Convergent Proteinuria Reduction across Distinct Therapeutic Pathways in IgA Nephropathy
3个月前
已关闭
Convergent Proteinuria Reduction across Distinct Therapeutic Pathways in IgA Nephropathy
3个月前
已关闭
A case of adrenal insufficiency after initiation of targeted-release budesonide formulation (Nefecon) in a patient with IgA nephropathy
3个月前
已完结
Endothelin Receptor Antagonist Ambrisentan, SGLT2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy
3个月前
已完结
Telitacicept Add Glucocorticoids Versus Telitacicept Alone in the Treatment of IgA Nephropathy: A Real‐World Study
3个月前
已完结
A targeted-release formulation of budesonide for the treatment of IgA nephropathy patients with severe renal impairment
8个月前
已完结
Efficacy and Safety of Nefecon in Patients with Immunoglobulin A Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
9个月前
已完结
Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
9个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
10个月前
已完结
皖公网安备34019202002308
